论文部分内容阅读
目的探讨血浆microRNA-30a(miRNA-30a)在乳腺癌(breast carcinoma,BC)中的表达及其临床意义。方法收集本院肿瘤外科收治的85例乳腺癌患者,并以同期62例健康志愿者作为对照组,检测乳腺癌患者和健康志愿者血浆miRNA-30a的表达水平。结果乳腺癌血浆中miRNA-30a血浆表达水平低于对照组,差异有统计学意义(P<0.01)。以miRNA-30a表达量0.837 9为诊断界点,此时诊断乳腺癌患者的敏感度、特异度分别为70.6%及64.5%。将乳腺癌患者按TNM分期比较诊断敏感度时,发现血浆miRNA-30a诊断TNM分期Ⅰ期乳腺癌患者敏感度最高(73.7%),DCIS期敏感度最低(50.0%),诊断早期乳腺癌敏感度为72.0%。血浆miRNA-30a表达量与TNM临床分级及其他临床病理因素均无明显相关性(P>0.05)。结论血浆miRNA-30a表达水平对诊断乳腺癌有一定帮助。
Objective To investigate the expression of plasma microRNA-30a (miRNA-30a) in breast carcinoma (BC) and its clinical significance. Methods Totally 85 breast cancer patients admitted to our hospital were enrolled in this study. 62 healthy volunteers were enrolled in this study. Plasma miRNA-30a levels were measured in breast cancer patients and healthy volunteers. Results The plasma level of miRNA-30a in breast cancer was lower than that in control group (P <0.01). With the miRNA-30a expression level of 0.8379 as the diagnostic cutoff point, the sensitivity and specificity of diagnosis of breast cancer patients were 70.6% and 64.5% respectively. When comparing the diagnostic sensitivity of breast cancer patients by TNM staging, we found that the highest sensitivity of plasma miRNA-30a in stage I breast cancer patients with TNM staging was 73.7%, the lowest was DCIS stage (50.0%), and the sensitivity of early stage breast cancer diagnosis Is 72.0%. Plasma miRNA-30a expression levels and TNM clinical grade and other clinicopathological factors were not significantly correlated (P> 0.05). Conclusion The expression level of plasma miRNA-30a may be helpful in the diagnosis of breast cancer.